Haymaker Acquisition Corp. III Merges with Biote
June 3, 2022
Haymaker Acquisition Corp. III, a publicly traded SPAC, completed its merger with consumer-directed hormone optimization company Biote (transaction announced Dec 13, 2021; closed May 27, 2022). Biote operates a platform that trains and certifies practitioners and provides practice management software, marketing support and branded nutraceutical products, and had grown a network of roughly 4,700 Biote-certified practitioners in the U.S.
- Buyers
- Haymaker Acquisition Corp. III
- Targets
- Biote
- Industry
- Healthcare Services
- Location
- Texas, United States
- Transaction Type
- Buyout
Explore More
Related Acquisitions
-
Instinct Bio Completes Business Combination with Relativity Acquisition Corp. and Begins Nasdaq Trading as BIOT
July 23, 2026
Healthcare Services
Instinct Bio Technical Company Holdings Inc. completed its previously announced business combination with Relativity Acquisition Corp., positioning the company as a publicly listed regenerative medicine and longevity platform. Following closing, Instinct Bio’s common stock and warrants began trading on Nasdaq on July 24, 2026 under tickers BIOT and BIOTW.
-
Merck KGaA to Acquire Bio-Techne for $11.3 Billion
June 25, 2026
Healthcare Services
Merck KGaA has entered a definitive agreement to acquire Bio-Techne for $73 per share in an all-cash transaction valued at about $11.3 billion (enterprise value). The deal is expected to close in late 2026 or early 2027, subject to regulatory approvals and Bio-Techne shareholder approval.
-
SunTx Capital Partners’ Suncrete Completes Business Combination with Haymaker Acquisition Corp. 4
October 9, 2025
Industrial Services
SunTx Capital Partners’ portfolio company Concrete Partners Holding, LLC (Suncrete) completed its business combination with Haymaker Acquisition Corp. 4, creating Suncrete, Inc. (PubCo), expected to begin trading on Nasdaq under ticker “RMIX.” The deal included PIPE funding and was approved by Haymaker shareholders and warrantholders in early April 2026.
-
HTL Biotechnology Acquires Modern Meadow's Beauty & Biomedical Division
May 6, 2024
Biotechnology
HTL Biotechnology has acquired the beauty and biomedical division of American company Modern Meadow, including its recombinant proteins platform and leading human recombinant collagen type III (rhCOL3) technology. The deal expands HTL's biopolymer portfolio and R&D/manufacturing capabilities, strengthens its presence in North America, and accelerates development of cosmetic and medical-grade recombinant collagen products.
-
biote Corp Acquires Asteria Health
January 17, 2024
Healthcare Services
biote Corp. (NASDAQ: BTMD) announced a definitive agreement to acquire F.H. Investments, Inc., doing business as Asteria Health, a privately held 503B manufacturer of compounded bioidentical hormones. The deal is intended to strengthen biote’s control over its supply chain through vertical integration of hormone product manufacturing and expand biote’s capabilities in 503B manufacturing and product development.
-
Bioceres Crop Solutions Merges With Marrone Bio to Create Global Sustainable Agriculture Leader
July 12, 2022
Healthcare Services
Bioceres Crop Solutions Corp. and Marrone Bio Innovations entered into a definitive all-stock merger agreement to combine their businesses. Under the terms, each share of Marrone Bio common stock would be exchanged at a fixed ratio for Bioceres ordinary shares, creating a global platform in biological crop protection, plant health, and seed care solutions.
Build a buyer list for your deal
Find active buyers from recent acquisition patterns and move straight into outreach.